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Supplementary Table S1. List of strains used in this study 
 
Fungal Strains  Source Description 
 C. auris 381 CDC  Drug sensitive isolate 
 C. auris 382 CDC  Drug sensitive isolate 
 C. auris 383 CDC  Clinical isolate exhibiting resistance to fluconazole
 C. auris 384 CDC Clinical isolate exhibiting resistance to fluconazole and  Voriconazole
 C. auris 385 CDC  Resistant to fluconazole, itraconazole, voriconazole, andamphotericin B 
 C. auris 386 CDC   Resistant to fluconazole, voriconazole, and amphotericin B
 C. auris 387 CDC  Drug sensitive isolate 
 C. auris 388 CDC  Resistant to fluconazole, itraconazole, voriconazole, and  amphotericin B- overexpression of CDR1 
 C. auris 389 CDC  Resistant to fluconazole, itraconazole, voriconazole, and  amphotericin B- overexpression of CDR1 
 C. auris 390 CDC  Resistant to fluconazole, itraconazole, and amphotericin B-   overexpression of MDR1 and CDR1 
  C. albicans SC5314 ATCC  Wild-type strain
 C. albicans ATCC MYA-573 ATCC  Fluconazole-resistant bloodstream isolate (from an AIDS patient in Germany) 






  Fluconazole-resistant clinical isolate that has increased efflux
  activity (MDR1 overexpression) and overexpression of the azole 
 target (ERG11)
  C. albicans TWO7243   Fluconazole- and itraconazole-resistant clinical isolate that has    increased mRNA levels of CDR1, MDR1, and ERG11
 C. glabrata ATCC-66032 ATCC Not available 
   C. glabrata ATCC-64677 ATCC Not available 
  C. glabrata ATCC-15126 ATCC Not available 
  C. krusei CAB39-6420  Bei Resources  Human blood isolate
  C. krusei ATCC-14243 ATCC Not available 
  C. krusei ATCC-34135 ATCC   Clinical specimen isolated in Minnesota, USA
   C. tropicalis ATCC-13803 ATCC Not available 
  C. tropicalis ATCC-1369 ATCC Not available 
   C. parapsilosis ATCC-22019 ATCC   Clinical specimen isolated in Puerto Rico
   C. parapsilosis CAB50-2638  Bei Resources  Human blood isolate
 
  
Supplementary Table S2. List of primers 
 

























   
 
 
       
         




    
    
        
        
        
        
        
        
        
        
        
        
        
        
         
         





Alone Combined Alone Combined
C. albicans SC-5314 > 128 8 0.25 0.0156 0.13 SYN
C. albicans ATCC-MYA 573 > 128 8 1 0.25 0.31 SYN
C. albicans TWO743 > 128 8 1 0.25 0.31 SYN
C. albicans TWO741 > 128 8 0.5 0.0625 0.19 SYN
C. glabrata ATCC-64677 > 128 2 0.5 0.5 1.02 IND
C. glabrata ATCC-15126 > 128 2 0.25 0.25 1.02 IND
C. glabrata ATCC-66032 > 128 2 0.5 0.5 1.02 IND
C. krusei CAB 396420 > 128 8 0.5 0.0625 0.187 SYN
C. krusei ATCC-14243 > 128 8 0.25 0.015 0.13 SYN
C. krusei ATCC-34135 > 128 8 0.5 0.062 0.19 SYN
C. tropicalis ATCC-13803 > 128 8 0.25 0.062 0.31 SYN
C. tropicalis ATCC-1369 > 128 2 0.5 0.031 0.08 SYN
C. parapsilosis ATCC-22019 > 128 8 0.25 0.062 0.31 SYN
C. parapsilosis CAB-502638 > 128 8 0.25 0.062 0.31 SYN
*ΣFICI (fractional inhibitory concentration index) is used to measure the interaction between the tested 
combinations. ΣFICI interpretation corresponded to the following definitions: synergism (SYN), ΣFICI ≤
0.5; additivity (ADD), ΣFICI > 0.5 and ≤ 1; and indifference (IND), ΣFICI > 1 and ≤ 4.
  Supplementary Table S4 - Significantly upregulated GO terms in APR/ITC treatment group 
 
 Category GOID Description Gene   Ratio  BgRatio   P value Padj 
Gene  
ID Count 









           
  
 
       










      
 
 





      
 
 
         
        
 
 





      
    
      
    
      
Supplementary Table S5- Significantly downregulated GO terms in APR/ITC treatment group
Category GOID Description GeneRatio BgRatio P value Padj Gene ID Count
BP GO:00 30001
Metal ion









































BP GO:00 06812 Cation transport 3/11 55/1815 0.00366 0.00912
40027445/4002766 
3/40028877 3























2/11 30/1815 0.01325 0.02063 40027445/4002766 3 2
    
      
        
 
 














    
 
 
    
    
 
 




















      
   
  
      
  
  






2/11 31/1815 0.01411 0.02063 40027445/4002766 3 2






















































































3/12 66/2359 0.00384 0.01249 40027445/4002766 3/40028877 3
